Clinical trials: Thymus Cancer
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Malignant Thymoma
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
The intent of the study is to assess the antitumor activity of PHA-848125AC in patients with recurrent or metastatic, unresectable malignant thymoma previously treated with multiple lines of chemotherapy.
- Trial name
- NCT01301391
- Testing
- Milciclib Maleate
- Where
- 3 sites in United States, Italy
- Volunteers
- 30 people
- Sponsor
- Tiziana Life Sciences LTD
Unresectable Thymic Carcinoma
A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas
This is a non-randomized, open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of sacituzumab tirumotecan (hereafter referred to as sac-TMT) in patients with unresectable thymic…
- Trial name
- XANTHOS (NCT07750353)
- Testing
- Sacituzumab Tirumotecan (Sac-TMT)
- Where
- 3 sites in Japan
- Volunteers
- 35 people
- Sponsor
- National Cancer Center, Japan
Thymoma, Thymic Carcinoma
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Background: Thymoma and thymic carcinoma are cancers originating in the thymus gland. Platinum-based chemotherapy is standard treatment for them.
- Trial name
- NCT03076554
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Thymic Tumors
A Study of KC1036 in Patients with Advanced Thymic Tumors
This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.
- Trial name
- NCT05683886
- Testing
- KC1036
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Cancer
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies.
- Trial name
- NCT01325441
- Testing
- BBI608, Paclitaxel
- Where
- 22 sites in United States, Canada
- Volunteers
- 565 people
- Sponsor
- Sumitomo Pharma America, Inc.
Thymoma, Advanced Thymic Epithelial Tumor
Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy
The purpose of this study is to evaluate the safety, tolerability and effectiveness of selinexor in patients with advanced thymic epithelial tumor progressing after primary chemotherapy.
- Trial name
- SELECT (NCT03193437)
- Testing
- Open Label Selinexor
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Georgetown University
Thymoma Staging, Clinical Presentations
Characteristics of Patients With Thymoma in Chulalongkorn Hospital
The purpose of this study is to study characteristics of patients with thymoma in Chulalongkorn hospital between 2003-2007.
- Conditions
- Thymoma Staging, Clinical Presentations, Associated Disorders, Laboratory Findings
- Trial name
- NCT01123590
- Where
- Thailand
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Thymoma, Thymic Carcinoma
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
To study the efficacy of Alimta as a single agent in thymic cancers
- Trial name
- NCT00198133
- Testing
- Premetrexed (Alimta)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Patrick Joseph Loehrer Sr.
Thymic Cancer
A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor
This is a phase II single center, open-label, single arm study of palbociclib treatment in patients with recurrent or metastatic advanced TETs after failure of one or more cytotoxic chemotherapy regimens.
- Trial name
- NCT03219554
- Testing
- Palbociclib
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Carcinoma, Thymic
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
This is a phase II, open-label, single-arm, multicenter study of the efficacy and safety of atezolizumab treatment in participants with advanced thymic carcinoma who failed prior systemic therapy.
- Trial name
- NCT04321330
- Testing
- Atezolizumab
- Where
- 10 sites in China
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Radiation Therapy and Thymus Function in Young Women With Breast Cancer
Breast cancer treatment sometimes includes radiation to the breast or chest wall. There is a small gland, called the thymus, located in the upper chest that may receive a small amount of the radiation aimed at the breast.
- Trial name
- NCT07725172
- Testing
- Blood draw for the laboratory assessment
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Duke University
Carcinoma, Non-Small-Cell Lung, Mesothelioma
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer
- Trial name
- NCT03023319
- Testing
- Bosutinib, Pemetrexed
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nagla Abdel Karim
Thymic Epithelial Tumor, Thymic Carcinoma
Molecular Analysis and Treatment Options of Thymic Malignancies
Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death.
- Conditions
- Thymic Epithelial Tumor, Thymic Carcinoma, Thymic Cancer
- Trial name
- NCT05667948
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer, Malignant Mesothelioma
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma
- Trial name
- NCT00024076
- Testing
- radiofrequency ablation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Thymoma, Computed Tomography
Prognostic Factors in Patients Submitted to Surgical Treatment for Thymoma
Thymoma is the most common primary tumor of the anterior mediastinum. Complete surgical resection is the mainstay of treatment of these tumors.
- Conditions
- Thymoma, Computed Tomography, Staging, Histology
- Trial name
- NCT04577495
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Thymoma
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
This study is designed to investigate whether adjuvant radiotherapy after complete resection has a better survival for stage II or III thymoma.
- Trial name
- NCT02633553
- Testing
- adjuvant radiotherapy
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Fudan University
Thymus Carcinoma
Ivonescimab for the Treatment of Thymic Cancer
This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may…
- Trial name
- NCT06980077
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Thyroid Cancer
A New Surgical Strategy to Protect the Inferior Parathyroid
The incidence of temporary hypoparathyroidism after thyroid surgery is 14%-60%, and the incidence of permanent hypoparathyroidism is 4%-11%.
- Trial name
- NCT05758025
- Testing
- Resection based on "thymus-vascular-inferior parathyroid" complex
- Where
- China
- Volunteers
- 506 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Thymoma, Thymus Neoplasms
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Background: Sunitinib is drug that is approved for treating various types of cancers, including kidney cancers. However, it has not been approved to treat cancers of the thymus.
- Trial name
- NCT01621568
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)